These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, report not yet due||2007-005241-38||A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) wit...||2008-09-24||not-yet-due|
|Not reported||2009-012705-19||A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid A...||2010-09-30||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2009-016973-13||A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome||2014-02-12||bad-data|
|Not reported||2011-003532-32||Phase 2 Assessment of the Relationship between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Preliminar...||2013-09-03||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2012-003460-47||A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not ...||2016-03-17||bad-data|
|Reported results||2013-001543-31||A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome||2016-04-20||due-trials|
|Listed as ongoing, but also has a completion date||2013-002596-18||A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)||2018-09-12||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2014-005153-39||A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type 1...||2017-06-23||bad-data|
|Reported results||2015-001709-15||A Phase 3, Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes||2017-05-18||due-trials|